Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176891 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant w/Laronidase for Hurler
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00176891 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 25 participants.
The verdict
NCT00176891, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Laronidase ERT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176891
The ClinicalTrials.gov registry entry for NCT00176891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00176891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176891 about?
NCT00176891 is a clinical study titled "Stem Cell Transplant w/Laronidase for Hurler". The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.
What is the current status of trial NCT00176891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00176891?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Laronidase ERT (DRUG).
Who is sponsoring clinical trial NCT00176891?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.